Onco360 now part of limited distribution network for Zydelig

NEW YORK — Onco360, an independent oncology pharmacy and clinical support services company, announced that it has been selected to be part of the highly limited specialty pharmacy network of Zydelig tablets.



The Food and Drug Administration recently approved Zydelig for the treatment of three different B-cell blood cancers. It can be used in combination with rituximab for patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy; as monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least two prior systemic therapies; and as monotherapy for patients with small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.



“This selection is an important milestone in Onco360’s strategy to offer an innovative, diversified portfolio of pharmacy and clinical solutions,” said Burt Zweigenhaft, vice chairman of Onco360. “We have confidence in the potential of Zydelig to achieve a strong market share position and further bolster our leadership in the specialty oncology pharmacy market. This relationship also continues to enhance our mission of providing the highest level of support to those battling cancer and helping treat the unmet needs of thousands of people afflicted with life-threatening illness.”



Zydelig is immediately available for order through Onco360 and its network of OncoMed Pharmacies.